Last updated: February 15, 2026
What Is NDC 72888-0032?
NDC 72888-0032 is a branded medication manufactured by Xywav, a formulation of gamma-hydroxybutyrate (GHB). It is primarily approved for narcolepsy with cataplexy and idiopathic hypersomnia. Approved by the FDA in 2020, Xywav is marketed by Jazz Pharmaceuticals. Its formulation offers a lower sodium content compared to its predecessor, Xyrem, appealing to patients requiring sodium restrictions.
Market Size and Growth Drivers
Prevalence of Target Conditions
- Narcolepsy affects approximately 1 in 2,000 people in the U.S., estimated at 150,000 to 200,000 patients.
- Idiopathic hypersomnia prevalence is less precise but is believed to affect roughly 40% of narcolepsy patients or around 60,000 individuals in the U.S.
Market Penetration
- As of early 2023, Xywav holds a dominant position in the narcolepsy market alongside Xyrem.
- The drug's advantage of reduced sodium content has been a key driver of physician preference, supporting growth.
- Current market share estimates suggest approximately 40–50% of the narcolepsy treatment market for the JZAR class.
Competitive Landscape
- Main competitors include Xyrem (sodium oxybate), Solriamfetol, Pitolisant, and Modafinil.
- Xywav's patent exclusivity runs until at least 2030, with potential extensions pending patent disputes and formulation protections.
Pricing and Revenue
Current Pricing
- For a 30-day supply, the average wholesale price (AWP) around mid-2023 is approximately $31,000.
- Medicaid and commercial payers often negotiate discounts, with net prices likely 20–30% lower.
| Parameter |
Value |
| List Price (per 30-day supply) |
$31,000 |
| Estimated Net Price |
$21,700–$24,800 |
| Annual Revenue per Patient |
$261,000 (assuming full treatment) |
Market Revenue
- Estimated total market revenue for Xywav exceeds $500 million annually, considering initial uptake, growth, and existing patients.
- Projections for 2023 suggest a compound annual growth rate (CAGR) of approximately 8-10% based on increasing diagnoses, patient switching from Xyrem to Xywav, and expanding approved indications.
Price Projections (2024 - 2028)
| Year |
Projected List Price |
Estimated Net Price |
Market Share |
Approximate Revenue |
| 2024 |
$32,000 |
$22,400 |
45% |
$600 million |
| 2025 |
$33,000 |
$23,100 |
50% |
$650 million |
| 2026 |
$34,000 |
$23,800 |
52% |
$700 million |
| 2027 |
$35,000 |
$24,500 |
55% |
$750 million |
| 2028 |
$36,000 |
$25,200 |
58% |
$800 million |
Price increases reflect inflation, steady payer negotiations, and ongoing market penetration.
Regulatory and Patent Considerations
- Patent protections sustain market exclusivity through at least 2030.
- Any new formulations or delivery systems could extend exclusivity further.
- Pending patent disputes might temporarily impact pricing strategies or market share dynamics.
Market Risks and Opportunities
- The introduction of generic sodium oxybate formulations could erode Xywav’s market share post-2030.
- Emerging therapies, like novel wakefulness agents (e.g., Solriamfetol, Pitolisant), could limit growth.
- Expanding indications to other sleep or neurological conditions might open additional revenue streams.
Key Takeaways
- Current Market: Xywav dominates a niche but essential treatment market for narcolepsy and hypersomnia, with annual revenues exceeding $500 million.
- Pricing: The average wholesale price is approximately $31,000 for a 30-day supply; net prices after discounts are roughly 70% of list prices.
- Projections: Revenue growth is expected to accelerate through 2028, reaching near $800 million annually, supported by increased diagnosis rates and expanding market share.
- Competitive Risks: Patent expiry and generic entry are the primary threats beyond 2030, with the potential to significantly reduce pricing power.
FAQs
1. How does Xywav compare to Xyrem in terms of pricing?
Xywav's list price is comparable to Xyrem, approximately $31,000 per 30-day supply, but its lower sodium content provides a competitive advantage that maintains market share.
2. What is the primary driver of Xywav's market growth?
Increasing diagnosis of narcolepsy and hypersomnia, physician preference for its safety profile, and stable patent protection drive growth.
3. Are there upcoming regulatory changes that could impact pricing?
Patent expirations around 2030 pose a risk; no imminent regulatory changes expected to immediately affect pricing but could initiate pricing pressures post-patent.
4. How might new therapies impact Xywav’s market?
Emerging wakefulness-promoting drugs and potential oral formulations of sodium oxybate could challenge Xywav's market share.
5. What are the key risks to price stability?
Patent expiration, payer negotiations, and the entry of generics are the primary risks to maintaining current prices.
References
[1] FDA Approval Documents for Xywav, 2020.
[2] Jazz Pharmaceuticals Market Reports, 2023.
[3] IQVIA Data on Sleep Disorder Medications, 2023.
[4] Industry Price Benchmarks, 2023.
